Particle.news
Download on the App Store
3 ARTICLES
·
2d ago

Nektar Therapeutics Stock Surges 150% After Eczema Drug Trial Success

Rezpegaldesleukin hit all key endpoints in a 16-week global trial, fueling acquisition interest in the cash-strapped biotech.

Image
A new immunotherapy injection has provided significant relief to eczema sufferers
Image

Overview

  • The global Phase 2b REZOLVE-AD trial enrolled 393 patients with moderate-to-severe atopic dermatitis and delivered three subcutaneous doses of rezpegaldesleukin over 16 weeks.
  • The treatment significantly improved the Eczema Area and Severity Index and produced rapid itch relief without raising rates of conjunctivitis or oral ulcers common with some biologics.
  • Investors bid Nektar’s shares up 150% on June 24, sending its market value well above the pre-trial $250 million and highlighting confidence in the drug’s commercial prospects.
  • With about 31.6 million Americans affected by atopic dermatitis and some patients unresponsive to existing therapies, rezpegaldesleukin addresses a sizable unmet need.
  • The trial’s success has drawn acquisition interest from larger pharmaceutical firms and set the stage for rezpegaldesleukin to target peak annual sales over $2 billion if approved.